Show simple item record

Anaplastic Lymphoma Kinase (ALK)-Rearranged Renal Cell Carcinoma: A Case Report Highlighting Diagnostic Challenges and Therapeutic Opportunities.

dc.contributor.authorElhassan, Eltayeb
dc.contributor.authorGirleanu, Corina
dc.contributor.authorKelly, Paul
dc.contributor.authorPower, Derek G
dc.contributor.authorSweeney, Paul
dc.contributor.authorMayer, Nick
dc.contributor.authorBambury, Richard M
dc.date.accessioned2024-10-04T11:20:11Z
dc.date.available2024-10-04T11:20:11Z
dc.date.issued2024-07-29
dc.identifier.issn2168-8184
dc.identifier.pmid39205743
dc.identifier.doi10.7759/cureus.65621
dc.identifier.urihttp://hdl.handle.net/10147/643021
dc.descriptionA 57-year-old male underwent an open right radical nephrectomy in 2015 for a 3-cm kidney tumor which was classified at the time as a combined tubulocystic and collecting duct carcinoma. One of six nodes was positive for metastatic carcinoma and the patient received adjuvant carboplatin/gemcitabine chemotherapy. In 2020, he developed enlarging retroperitoneal adenopathy and underwent a retroperitoneal lymph node dissection with 11 of 13 nodes in the resected specimen positive for the previously described renal carcinoma, followed by adjuvant radiotherapy. In November 2022, he again underwent surgery for further locoregional recurrence with resection of a right psoas mass lesion and right hemicolectomy. Pathology on this occasion was reclassified as anaplastic lymphoma kinase-rearranged renal cell carcinoma (ALK-RCC). Shortly afterward, a restaging CT revealed multiple liver metastases and evidence of further disease recurrence in the right renal bed. He commenced alectinib with a complete radiological response and has continued on it for 12 months at the time of writing this report. To our knowledge, there are only five prior reports of ALK-RCC treated with targeted ALK inhibitor therapy in the literature. We report this case to highlight the importance of recognizing and diagnosing this rare RCC subtype since it has significant therapeutic implications. Furthermore, to our knowledge, this patient has had the longest follow-up reported to date in the literature so far. A concerted effort by the histopathology and oncology community is needed to gather more data on the incidence and treatment outcomes of these tumors so that progress can be made in optimizing their management. It is important to consider novel and emerging entities from the most recent WHO 2022 classification, many of which are defined by molecular characteristics with associated therapeutic implications.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesHSE Library Open Access Research Awards 2024en
dc.rightsCopyright © 2024, Elhassan et al.
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectalectiniben_US
dc.subjectanaplastic lymphoma kinaseen_US
dc.subjectcarboplatinen_US
dc.subjectCarcinomaen_US
dc.subjecthistopathology (hp)en_US
dc.subjectkidney canceren_US
dc.subjectnephrectomyen_US
dc.subjectONCOLOGYen_US
dc.subjectrenal cell carcinoma (rcc)en_US
dc.titleAnaplastic Lymphoma Kinase (ALK)-Rearranged Renal Cell Carcinoma: A Case Report Highlighting Diagnostic Challenges and Therapeutic Opportunities.en_US
dc.typeArticleen_US
dc.identifier.journalCureusen_US
dc.source.journaltitleCureus
dc.source.volume16
dc.source.issue7
dc.source.beginpagee65621
dc.source.endpage
refterms.dateFOA2024-10-04T11:20:13Z
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
cureus-0016-00000065621.pdf
Size:
4.311Mb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record

Copyright © 2024, Elhassan et al.
Except where otherwise noted, this item's license is described as Copyright © 2024, Elhassan et al.